A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
A legfontosabb adatok
- Ki végzi
- GlaxoSmithKline
- Hol
- Anniston, Austin, Charlottesville, Fair Oaks, Little Rock, Miami, Miami Lakes, Newport News, San Diego, Seattle, Stockbridge és West Palm Beach (Egyesült Államok)Mind a 12 helyszín megnézéseMég 1 másik országban, 1 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 225 fő, tervezett
- Kezdés
- 2026. márc. 9.
- Várható befejezés
- 2027. jún. 3.
- A vizsgálat típusa
- Beavatkozással járó, 5 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine
- Licensed Seasonal Influenza Vaccine
- Licensed COVID-19 Vaccine
- A regiszteradat frissítve
- 2026. június 30.
Ki vehet részt
- Életkor
- 65 év – 85 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol independently or with the assistance of the caregiver
- Informed consent obtained from the participant prior to performance of any study-specific procedure
- A male or female 65 to 85 years of age (YoA) (inclusive) at the time of screening
- Healthy participants or medically stable patients as established by medical history and clinical examination
- Other protocol-defined inclusion criteria may apply
Ki nem vehet részt
- History of symptomatic influenza/ SARS-CoV-2 infection confirmed by local health authority-approved testing methods within 180 days (for influenza) or 90 days (SARS-CoV-2 infection) prior to study intervention administration
- History of Guillain-Barré syndrome (GBS) within 6 weeks of receiving any vaccine
- History of hypersensitivity or allergic reaction to any previous influenza or COVID-19 vaccine
- History of hypersensitivity or allergic reaction to any previous mRNA vaccine
- Administration of any influenza vaccine within 181 days before the study intervention administration (Day -180 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration
- Administration of a SARS-CoV-2 antigen-containing vaccine in the period starting 91 days before the study intervention administration (Day -90 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration
- Administration of any mRNA-based vaccine in the period starting 29 days before the study intervention administration (Day -28 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration
- Administration of any other vaccine not foreseen by the study protocol in the period starting 29 days (Day -28 to Day 1) before the study intervention administration or planned administration within 28 days (Day 29) after the study intervention administration
- History of or current suspicion of myocarditis or pericarditis (including following administration of an mRNA vaccine); or idiopathic cardiomyopathy, or presence of any medical condition that increases the risk of myocarditis or pericarditis, including cocaine abuse, cardiomyopathy, endomyocardial fibrosis, hypereosinophilic syndrome, hypersensitivity myocarditis, eosinophilic granulomatosis with polyangiitis and persistent myocardial infection
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s)
- Any clinically significant laboratory abnormality
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required)
- Acute or unstable chronic conditions, clinically significant pulmonary, cardiovascular, or renal functional abnormality, as determined by physical examination and/or laboratory screening tests
- Current or past malignancy, unless completely resolved without clinically significant sequelae (e.g., no evidence of disease following successful treatment of basal cell carcinoma cases are allowed) for >5 years
- Other protocol-defined exclusion criteria may apply
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 65 és 85 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
Még 1 másik országban, 1 helyszínen
- Anniston, AlabamaHospital not named in the registryContact: Almena Free (principal investigator)Résztvevőt keres
- Austin, TexasHospital not named in the registryContact: Cary Douglass (principal investigator)Résztvevőt keres
- Charlottesville, VirginiaHospital not named in the registryContact: James Clark (principal investigator)Résztvevőt keres
- Fair Oaks, CaliforniaHospital not named in the registryContact: Masaru Oshita (principal investigator)Résztvevőt keres
- Little Rock, ArkansasHospital not named in the registryContact: Derek Lewis (principal investigator)Résztvevőt keres
- Miami, FloridaHospital not named in the registryContact: Rafael Ubeda (principal investigator)Résztvevőt keres
- Miami Lakes, FloridaHospital not named in the registryContact: Jose Cardona (principal investigator)Résztvevőt keres
- Newport News, VirginiaHospital not named in the registryContact: George Freeman (principal investigator)Résztvevőt keres
- San Diego, CaliforniaHospital not named in the registryContact: Donald Brandon (principal investigator)Résztvevőt keres
- Seattle, WashingtonHospital not named in the registryContact: Rebecca Dunsmoor-Su (principal investigator)Résztvevőt keres
- Stockbridge, GeorgiaHospital not named in the registryContact: Jon Finley (principal investigator)Résztvevőt keres
- West Palm Beach, FloridaHospital not named in the registryContact: Mira Baron (principal investigator)Résztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The study will assess any side effects or health issues, and additional blood samples will be collected at specific times to evaluate how well participants bodies build protection against the flu and COVID-19.
A vizsgálat 5 csoportja
- FLU/COVm_Dose Level 1A vizsgált kezelés
Participants receive a single intramuscular administration of the investigational mRNA Seasonal Flu/COVID-19 combination vaccine at dose level 1 (Lowest dose).
Kezelés: Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine
- FLU/COVm_Dose Level 2A vizsgált kezelés
Participants receive a single intramuscular administration of the investigational mRNA Seasonal Flu/COVID-19 combination vaccine at dose level 2 (Medium dose).
Kezelés: Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine
- FLU/COVm_Dose Level 3A vizsgált kezelés
Participants receive a single intramuscular administration of the investigational mRNA Seasonal Flu/COVID-19 combination vaccine at dose level 3 (Highest dose).
Kezelés: Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine
- Licensed Seasonal Influenza Vaccine GroupMár használt kezelés, összehasonlításként
Participants receive a single intramuscular administration of a licensed seasonal Flu vaccine.
Kezelés: Licensed Seasonal Influenza Vaccine
- Licensed COVID-19 Vaccine GroupMár használt kezelés, összehasonlításként
Participants receive a single intramuscular administration of a licensed COVID-19 vaccine.
Kezelés: Licensed COVID-19 Vaccine
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase 1, Observer-Blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of an Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
- Kérdések a feltételekről
- Forrás: NCT07464314: ki vehet részt
- A regiszteradat frissítve
- 2026. június 30.